Az Ospedaliero Universitaria di Ferrara

Slides:



Advertisements
Similar presentations
Advances and Emerging Therapy for Lung Cancer
Advertisements

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.
Neo-adjuvant Chemotherapy for Breast Cancer
Triple negative breast cancer
Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama
O VARIAN C ANCER C LINICAL T RIALS P LANNING M EETING Unanswered Questions in Upfront Therapy IP Therapy Issue Keiichi Fujiwara, MD, PhD Saitama Medical.
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.
Christine Simmons, MD MSc FRCPC Medical Oncologist, BCCA Vancouver
SON Breast Cancer Update: Current Controversies Oct 18, 2014 Who should we radiate and why? Lorna Weir Radiation Oncologist BC Cancer Agency, Vancouver.
HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER
Terapia Neoadiuvante nella malattia HER-2 positiva: Trasferibilità nella pratica clinica Vincenzo Adamo UOC Terapie Integrate in Oncologia AOU Policlinico.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
1 The Role of the Oncotype DX ® Breast Cancer Assay in the Neoadjuvant Setting.
Assistant Professor of Medicine Dana-Farber Cancer Institute
O’Shaughnessy J et al. Proc ASCO 2011;Abstract 1007.
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Neoadjuvant Endocrine Treatment in Breast Cancer Giorgio Mustacchi Centro Oncologico Università di Trieste.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Terapia Neoadiuvante Revisione delle evidenze scientifiche
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast.
High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial 1 San Antonio.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Adjuvant therapy of HER2 positive early breast cancer The Evidences Antonio Frassoldati Oncologia Clinica - Ferrara.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Neoadjuvant Therapy for Triple Negative Breast Cancer
Slamon D et al. SABCS 2009;Abstract 62.
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Neoadjuvant Therapy for HER2+ Disease
Management of the Axilla after Neoadjuvant Chemotherapy
Dr Amit Gupta Associate Professor Dept Of Surgery
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy Neil Love, MD1, Kimberly L Blackwell, MD2, Eleftherios.
Definitive Analysis of the Primary Outcomes
Direttore UOC di Oncologia Medica
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
ASCO Recap Palak Desai, MD.
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
IOV – Istituto Oncologico Veneto I.R.C.C.S.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
Metastatic HER2+ Breast Cancer: Resistance
Ospedale Misericordia, Grosseto
High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.
Barrios C et al. SABCS 2009;Abstract 46.
Neoadjuvant Therapy in HER2-Positive Breast Cancer
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Untch M et al. Proc SABCS 2010;Abstract P
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Optimizing Neoadjuvant Treatment for Primary Breast Cancer
Alan P. Venook, MD University of California, SF
Martin M et al. Proc SABCS 2012;Abstract S1-7.
Ali Shamseddine,MD,FRCP
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Clinical Focus.
Presentation transcript:

Az Ospedaliero Universitaria di Ferrara This house believes that neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm Discussion Antonio Frassoldati Oncologia Clinica Az Ospedaliero Universitaria di Ferrara

When a therapy becomes standard? Class I evidence of improvement in OS in respect with the previous standard If not for OS, evidence of improvement in DFS If not for OS and DFS, evidence of improvements in QoL, side effect profile or costs.

Neoadjuvant vs adjuvant Mauri, JNCI 2005

What is the benchmark? Results of adjuvant therapies Might NAST strategy improve this figure through a personalized approach? HER2+: B31/N9831, JCO 2011; TN : E1199, SABCS 2014, BCCA group

Challenge of demonstrating improved EFS with neoadjuvant therapy Presented By Angela DeMichele at 2015 ASCO Annual Meeting

Increased pCR rate with multiple antiHER2 agents Multiple block with chemotherapy plus T+L, or T+P, versus single block

Increased pCR rate with Carboplatin or Bevacizumab in TNBC Chen, PlosOne 2014

Prognostic Predictive The possibility to increase pCR does justify the neoadjuvant use? Prognostic Predictive Presented By Angela DeMichele at 2015 ASCO Annual Meeting

Trial-level correlation between treatment effect on pCR and outcome Little association between increase in frequency of pathological complete response and treatment’s effect on EFS or OS Cortazar, Lancet 2014

Why NAST results do not translate in long-term results? In most trials, heterogeneous tumour subtypes were enrolled: possible effect due to different response in different subtypes. A targeted therapy was used in only three trials (GeparQuattro, NOAH and TECHNO) (and adjuvant trastuzumab used only in NOAH): the degree of difference in pCR is important for long term outcome. Postoperative therapy could have partly contributed to the treatment effect. Factors unrelated to primary tumour response could have had a role.

NAST in more homogeneous tumors Patient-level Meta-Analysis azard Ratios for pCR vs No pCR in HER2+ BC Broglio, Jama Oncol 2016

Trial-level Treatment Benefit for pCR vs Corresponding EFS-HR Between Treatment Arms for Randomized Trials in HER2 BC Modest correlation with pCR odds ratio and EFS HR, but not with OS HR Broglio, Jama Oncol 2016

Why NAST should be the standard? Increase in the rate of breast conservation Improvement in axillary surgery (avoiding axillary clearence in cN1 pts) Increase in the disease outcome (DFS, DDFS, OS)? Increase the kwnoledge of the disease behavior (prognostic; useful for adjuvant phase) Increase in the possibility of tailoring therapies (to increase the pCR or the long term outcomes)

Response and survival to NAST of intrinsic subtypes n-pCR pCR Prat, BMCmed 2015

How precise we are in selection of the optimal candidate to NAST? Caray , ASCO 2013

PIK3CA mutation is associated with lower activity of anti-HER2 agents Loibl, Ann Oncol 2016

TN subtypes are associated with different probability of pCR with NAST Lehmann, PlosOne 2016

Odds ratio of pCR vs n-pCR by type of TN subtype classifier Lehmann, PlosOne 2016

pCR rate according to disease subtypes and TILs Carbognin, The Oncologist 2016

NAST: already standard or still a model for reasearch? Are the endpoints of therapy the same if therapy is given before or after surgery? Some of them can be influenced by the timing of therapy The tumor biology may not be the same for primary or micrometastatic tumor cells

Tumor dormancy of micrometastatic disease Evans, WJCO 2015

Clinical and Prognostic information How we practically use them (EBM guided)? Change the type of surgery Reassure the patient if pCR Change the adjuvant strategy Change the duration of treatments Change the type of radiation Change the type of controls during the follow-up

If NAST is standard, which standard after NAST? For HER2+ BC, trastuzumab up to one year can be considered standard (even if pCR?) What to do if HER2 status changes? (stop or go trastuzumab?) No established guideline for Chemo in tumors with residual disease at surgery (other chemo? which chemo?) No established radiotherapy strategy for cN+ becoming ypN0, nor for large tumor obtaining good PR but undergoing to mastectomy. (RT on axilla? RT after mastectomy? Maybe more questions than answers generated by NAST

Which lessons from the NAST story? Tumor selection is the first point – we are still imprecise Patient involvement in the decision is the second point – an honest discussion about the endpoints, the potential true benefits and the limits of NAST must be done NAST remains the best model to study the activity of new drugs and to evaluate the “in vivo” effects of them, even if it is not automatically the same in other tumor settings.

NAST in HER2+ & TNBC NAST is NOT the standard, but is one of the possible standards (to be carefully selected for the right situation)